Eli Lilly Stock Price Prediction: Where Will It Be in 1 Year
24/7 Insights Wall Street expectations for where Eli Lilly and Co.
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Zepbound and Mounjaro will add tens of billions in revenue to Eli Lilly's top line in the years ahead. But management is looking beyond those products and developing even more weight loss treatments.
Weight-loss drugs linked to rare vision loss: Harvard study
Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance he...
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Analysts revise Eli Lilly stock price targets
Eli Lilly (NYSE: LLY) recently made headlines with positive drug trial results for its GLP-1 weight-loss drug and its approval in China. But there might be some potential trouble ahead, as U.S. Pre...
FDA approves a new Alzheimer's drug from Eli Lilly
Evan Seigerman, BMO Capital Markets senior research analyst, joins 'Squawk Box' to discuss the FDA's approval of Eli Lilly's Alzheimer's drug donanemab, how much revenue it could add to Elil LIlly'...
Eli Lilly's Alzheimer's drug receives FDA sign-off
The Food and Drug Administration (FDA) has approved Eli Lilly and Co's (NYSE:LLY) new Alzheimer's drug, donanemab, to be sold under the brand name Kisunla. This monoclonal antibody infusion, admini...
FDA Approves Eli Lilly's Alzheimer's Drug Donanemab
The Food and Drug Administration on Tuesday approved donanemab for treating Alzheimer's disease, after clinical studies indicated Eli Lilly's drug could significantly slow cognitive decline, follow...
FDA approves Eli Lilly Alzheimer's drug, expanding treatment options in the U.S.
The Food and Drug Administration approved Eli Lilly's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting disease. It's a long-awaited win for Eli Lilly after ...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage o...
LLY & NVDA: Some of the Best Trends of All Time
Eli Lilly (LLY) and Nvidia (NVDA) are seeing some of the best trends of all time, notes Jerry Parker. He discusses trends to watch in the second half of the year.
Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.
Secured by a $159 billion order backlog, Lockheed Martin's dividend payments are as dependable as they get. Eli Lilly can help you cash in on the booming $130 billion weight-loss drug market.
This Is Massive News for Eli Lilly Investors
Eli Lilly has been working on a drug called donanemab to treat Alzheimer's disease. This market is estimated to reach more than $30 billion by the next decade.
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.
Eli Lilly is partnering with OpenAI to help research antimicrobial resistance (AMR) treatments. Research suggests that AI in the healthcare market could be a $187 billion opportunity by 2030.
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. Just look at Eli Lilly (NYSE: LLY ).
Related Companies